Prospective study on the validity of different eGFR estimation methods based on biomarkers in patients with allogeneic stem cell transplantatio

Not Applicable

Recruiting

• Conditions: patients with allogeneic stem cell transplantation; Z94.81

• Registration Number: DRKS00029715
• Lead Sponsor: niversitätsklinikum Hamburg-Eppendorf

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-09-19
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Adult, hospitalized patients of the Clinic and Polyclinic for Stem Cell Transplantation of the UKE, who are treated intravenously with one or more of the drugs ceftazidime, meropenem, piperacillin-tazobactam, vancomycin, aciclovir or ganciclovir according to the indication
• Written consent from the patient

Exclusion Criteria

• Age < 18 years
• Patients with cardiac pacemaker
• Pregnant women
• Lack of written consent from the patient

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlation of GFR estimates based on creatinine and cystatin C with the clearance of renally eliminated anti-infectives. GFR is calculated using various formulas (including Cockroft-Gault, MDRD, CKD-EPI). The clearance of renally eliminated anti-infectives is determined using population pharmacokinetic models.

Secondary Outcome Measures

Name	Time	Method
- The impact of muscle mass determined from imaging (CT) or by bioimpedance analysis (BIA) and the duration and intensity of steroid treatment (data from the electronic patient record) on the correlation of GFR estimates with the clearance of the anti-infectives examined. <br><br>- Correlation of drug clearance (from population pharmacokinetic calculations) and creatinine clearance accurately measured from serum and urine data, as a measure of actual renal function.